Clinical Trials Logo

Hepatitis, Chronic Active clinical trials

View clinical trials related to Hepatitis, Chronic Active.

Filter by:
  • None
  • Page 1

NCT ID: NCT00277238 Completed - Clinical trials for Hepatitis, Chronic Active

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Start date: February 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RBV) compared to PEG-IFN and RBV without CPG 10101 in HCV positive subjects who were classified as non-responders to previous adequate PEG-IFN plus RBV therapy.

NCT ID: NCT00142103 Completed - Clinical trials for Hepatitis, Chronic Active

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects

Start date: September 2005
Phase: Phase 1
Study type: Interventional

1. To characterize the tolerability profile of subcutaneous (SC) CPG 10101 alone, with pegylated interferon, ribavirin or both pegylated interferon and ribavirin when administered weekly for twelve weeks in relapsed HCV positive subjects. 2. To assess the effect of subcutaneous (SC) CPG 10101 alone, with pegylated interferon, ribavirin or both pegylated interferon and ribavirin on serum Hepatitis C Virus (HCV) RNA concentrations